Moleculin today announced that it has entered into a definitive agreement with institutional investors for a registered direct offering of securities with gross proceeds of approximately $9 million.
LivaNova today announced company executives will present at two upcoming healthcare conferences on March 13: the Barclays Global Healthcare Conference 2018 and the Cowen and Company 38th Annual Health Care Conference.
Moleculin Biotech today announced that, pursuant to its continued collaboration with MD Anderson it has developed and licensed what it believes is a major breakthrough in its effort to develop a new cancer treatment.
LivaNova today announced it has entered into an agreement to acquire TandemLife, a privately held company focused on advanced cardiopulmonary temporary support solutions.
Moleculin announced it has entered into an agreement with Emory University to enable research on the WP1066 molecule for the possible treatment of medulloblastoma.
Moleculin Biotech, Inc. today announced it has been able to show promising tumor suppression activity with its inhibitor of glycolysis, WP1122.
Bellicum Pharmaceuticals, Inc. today announced the appointment of William Grossman, M.D., Ph.D., as Chief Medical Officer, effective February 5. Dr. Grossman joins Bellicum from Genentech/Roche.
Bellicum today announced that the Company has received notice from the FDA that U.S. studies of BPX-501 have been placed on a clinical hold following three cases of encephalopathy deemed as possibly related to BPX-501.